US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
META
$728.08
▲+0.00%
NVDA
$233.95
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
JNJ
$256.03
▲+0.00%
SPCX
$158.96
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
META
$728.08
▲+0.00%
NVDA
$233.95
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
JNJ
$256.03
▲+0.00%
SPCX
$158.96
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by GlycoMimetics, Inc.
< Previous
1
2
Next >
GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals
June 05, 2025
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting
November 06, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma
October 29, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint
October 29, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan
July 25, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
June 04, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
May 29, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
May 06, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
April 25, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
March 27, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
March 13, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
February 26, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
February 12, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
January 04, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia
December 10, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference
November 09, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
November 03, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023
October 20, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687
September 06, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023
August 02, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023
July 19, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Announces Its Addition to the Russell Microcap® Index
June 26, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia
June 15, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference
May 31, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023
May 03, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023
April 26, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022
March 29, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023
March 16, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
< Previous
1
2
Next >
